Cargando…

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients

CMV infections are common after SOT. v-GCV is increasingly used in children. The aim of this study was to evaluate presently used dosing algorithms. Data from 104 pediatric SOT recipients (kidney, liver, and heart) aged 0.3–16.9 yr and receiving v-GCV once a day were used for model development and v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Åsberg, A, Bjerre, A, Neely, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880615/ https://www.ncbi.nlm.nih.gov/pubmed/24152053 http://dx.doi.org/10.1111/petr.12179

Ejemplares similares

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

1564. Lower Rates of Epstein–Barr Virus (EBV) Viremia in Pediatric Solid Organ Transplant (SOT) Recipients Who Received Valganciclovir Prophylaxis
por: Moulton, Elizabeth A, et al.
Publicado: (2018)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease
por: Vezina, Heather E, et al.
Publicado: (2009)

2646. Incidence of Myelosuppression Related to Valganciclovir Prophylaxis in Solid-Organ Transplant Recipients at High Risk of CMV Disease
por: Belga, Sara, et al.
Publicado: (2019)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

1703. Hematologic Toxicity of Valganciclovir Prophylaxis in Solid Organ Transplant Recipients as a Function of Weight-adjusted Ganciclovir Exposure
por: Campanella, Toni A, et al.
Publicado: (2020)

Efficacy of low-dose valganciclovir in CMV R+ lung transplant recipients: a retrospective comparative analysis
por: Hunt, Jessica, et al.
Publicado: (2021)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy
por: Kalil, Andre C., et al.
Publicado: (2009)

576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients
por: shi, yiyun, et al.
Publicado: (2020)

Infections in pediatric solid organ transplant recipients
por: Fonseca-Aten, Monica, et al.
Publicado: (2006)

Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach
por: Lalagkas, Panagiotis Nikolaos, et al.
Publicado: (2023)

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
por: Johansson, Inger, et al.
Publicado: (2013)

Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation
por: Cheyssac, Elodie, et al.
Publicado: (2023)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

Approach to vaccinating the pediatric solid organ transplant candidate and recipient
por: Kao, Carol M., et al.
Publicado: (2023)

Characterization of Cytomegalovirus Disease in Solid Organ Transplant Recipients by Markers of Inflammation in Plasma
por: Rollag, Halvor, et al.
Publicado: (2013)

1571. Cost-Effectiveness Analysis of Duration of Valganciclovir Prophylaxis Among CMV Serology Mismatched (Donor+/Recipient−) Lung Transplant Recipients
por: Tomko, Heather, et al.
Publicado: (2018)

Diarrhea in pediatric recipients of solid organ or bone marrow transplants
por: Phrommas, Jirachart, et al.
Publicado: (2021)

A quick algorithmic review on management of viral infectious diseases in pediatric solid organ transplant recipients
por: Moghadamnia, Marjan, et al.
Publicado: (2023)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

572. Antiviral Toxicities Among Pediatric Solid Organ Transplant Recipients
por: Downes, Kevin J, et al.
Publicado: (2020)

Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient—No Intervention Actually Needed
por: Åsberg, Anders, et al.
Publicado: (2020)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

1744. CMV Infection and Management Among Pediatric Solid-Organ Transplant Recipients
por: Sharova, Anna, et al.
Publicado: (2019)

Prevention and management of CMV infection in pediatric solid organ transplant recipients
por: Balani, Shanthi S., et al.
Publicado: (2023)

Trichodysplasia spinulosa successfully treated with adapalene 0.1% gel and oral valganciclovir in a renal transplant recipient
por: Shah, Pooja R., et al.
Publicado: (2019)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Infections in Solid-Organ Transplant Recipients
por: Singh, Nina, et al.
Publicado: (2015)

Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients
por: Kauffman, Carol A., et al.
Publicado: (2015)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

1003 The Impact of Cidofovir on the Renal Function of Pediatric Solid Organ Transplant Recipients
por: Florescu, Diana F., et al.
Publicado: (2014)

An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients
por: Min, Sandar, et al.
Publicado: (2021)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
por: Li, Po-Hsien, et al.
Publicado: (2021)

Pneumocystis Pneumonia in Solid-Organ Transplant Recipients
por: Iriart, Xavier, et al.
Publicado: (2015)

Primary Care of the Solid Organ Transplant Recipient
por: Ruzgar, Nensi Melissa, et al.
Publicado: (2021)

Respiratory Viruses in Solid Organ Transplant Recipients
por: Bitterman, Roni, et al.
Publicado: (2021)

Mycobacterial infections in solid organ transplant recipients
por: Rashid, Harun Ur, et al.
Publicado: (2021)

Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients
por: Chang, Yeh-Chung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cvlm3qkoea0adm8qm8c1osfm15